- Home
- DOCN vs IBRX Comparison
DOCN vs IBRX Comparison
Compare DOCN & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCN
- IBRX
- Stock Information
- Founded
- DOCN 2011
- IBRX 2014
- Country
- DOCN United States
- IBRX United States
- Employees
- DOCN N/A
- IBRX N/A
- Industry
- DOCN Retail: Computer Software & Peripheral Equipment
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DOCN Technology
- IBRX Health Care
- Exchange
- DOCN Nasdaq
- IBRX Nasdaq
- Market Cap
- DOCN 2.5B
- IBRX 2.4B
- IPO Year
- DOCN 2021
- IBRX N/A
- Fundamental
- Price
- DOCN $27.38
- IBRX $2.87
- Analyst Decision
- DOCN Buy
- IBRX Strong Buy
- Analyst Count
- DOCN 14
- IBRX 5
- Target Price
- DOCN $40.62
- IBRX $11.40
- AVG Volume (30 Days)
- DOCN 1.5M
- IBRX 10.1M
- Earning Date
- DOCN 08-07-2025
- IBRX 08-11-2025
- Dividend Yield
- DOCN N/A
- IBRX N/A
- EPS Growth
- DOCN 119.67
- IBRX N/A
- EPS
- DOCN 1.14
- IBRX N/A
- Revenue
- DOCN $806,588,000.00
- IBRX $31,222,000.00
- Revenue This Year
- DOCN $15.19
- IBRX $567.98
- Revenue Next Year
- DOCN $13.99
- IBRX $160.56
- P/E Ratio
- DOCN $24.18
- IBRX N/A
- Revenue Growth
- DOCN 13.21
- IBRX 10238.41
- 52 Week Low
- DOCN $25.45
- IBRX $1.83
- 52 Week High
- DOCN $47.02
- IBRX $7.63
- Technical
- Relative Strength Index (RSI)
- DOCN 42.67
- IBRX 49.40
- Support Level
- DOCN $26.75
- IBRX $2.77
- Resistance Level
- DOCN $28.28
- IBRX $3.24
- Average True Range (ATR)
- DOCN 1.07
- IBRX 0.23
- MACD
- DOCN -0.06
- IBRX -0.03
- Stochastic Oscillator
- DOCN 18.31
- IBRX 19.74
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups, and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. Geographically, the company generates maximum revenue from North America and also has a presence in Europe, Asia, and the Rest of the world.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.